The Establishment and Clinical Application of a Prediction Model of Lung Cancer Distant Metastasis Based on the Genomic Characteristics of Circulating Tumor Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-01

Study Completion Date

2022-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lung cancer is the most common type of cancer in my country, but the 5-year survival time of lung cancer patients is only 17%. Among them, the biggest reason that affects the patient's prognosis is the metastasis of the tumor. There are very few clinical methods suitable for the treatment of metastatic lung cancer, and the curative effect is not good. Therefore, early monitoring and interventions to prevent distant colonization of metastases are the key to improving the survival of lung cancer. The preliminary research of this project found that circulating tumor cells in peripheral blood can be used as an effective means for clinical diagnosis and treatment of lung malignant tumors. Through the analysis of the difference in time and space metastasis of lung cancer patients, it is found that the genomes of different metastasis stages and metastatic organs of lung cancer are quite different , And is closely related to the patient's survival. For this reason, we propose the hypothesis that the genomic mutation characteristics of circulating tumor cells can detect tumor metastasis signals earlier than CT imaging diagnosis. To test this hypothesis, we will develop a cancer metastasis risk assessment system based on tumor genomics. First, we collect big data on the genome of primary and metastatic lung cancer from public databases, and use statistical methods to screen out genomic features that are significantly related to metastatic lung cancer and its metastatic colonization organs. Secondly, using these features to develop a set of machine learning models that can determine the risk of metastasis of a lung cancer based on its genome features. Finally, we applied the model to clinical practice. By detecting the circulating tumor cells of patients with primary lung cancer during the reexamination, we established a statistical noise reduction model to extract the genomic characteristics, and then substituted into the model to determine the circulating tumor cells carried by the patient Whether there is a risk of recurrence and metastasis. By comparing the imaging data in the review, we will verify whether the model detects early metastasis signals of lung cancer earlier than imaging methods. Ultimately, our model will aggregate genomic markers related to metastasis risk, explore their drug targeting, and provide powerful big data analysis support for early intervention in metastasis colonization and prolonging the survival of lung cancer patients. If the topic is demonstrated, it will help to clarify the use of tumor genome big data analysis to reveal the genomic driver mutations of metastatic lung cancer; demonstrate the feasibility of circulating tumor cell genome driver mutations to predict the risk of lung cancer metastasis; and finally clarify the PI3K/Akt/mTOR signal Can inhibitors of the pathway be used as a target for early intervention in lung cancer metastasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

NCT06843707

Lung Cancer Lung Lung Cancer (NSCLC) +1 more

RECRUITING

Multi-omics Study of Early-stage Lung Cancer with Distinct Phenotypes

NCT06699979

Lung Cancer Associated with Cystic Airspaces Multiple Primary Lung Cancers Non-Small Cell Lung Cancer

RECRUITING

A Preliminary Study on the Detection of Plasma Markers in Early Diagnosis for Lung Cancer

NCT04558255

Lung Cancer

UNKNOWN

A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases

NCT03257735

Lung Cancer Brain Metastases Cerebrospinal Fluid +1 more

UNKNOWN

SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis

NCT06772363

Lung Cancers

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer CTCs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Shanghai General Hospital

blood sample

Intervention Type DIAGNOSTIC_TEST

Isolated the blood sample and detected the CTC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

Isolated the blood sample and detected the CTC

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with non-small cell lung cancer 18 to 75 years old, patients of any stage, with at least one measurable lesion on chest imaging, ECOG PS score: 0 to 1 point